

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | |
|--|--|--|
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 | | ATTORNEY'S DOCKET NUMBER 100725-48 (KGB) U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/535522 |
| INTERNATIONAL APPLICATION NO. PCT/EP2003/012941 | INTERNATIONAL FILING DATE 19 November 2003 (19.11.2003) | PRIORITY DATE CLAIMED 19 November 2002 (19.11.2002) |
| TITLE OF INVENTION Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases | | |
| APPLICANT(S) FOR DO/EO/US Alexander STEINKASSERER, Matthias LECHMANN, and Elisabeth ZINSER | | |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: | | |
| <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input checked="" type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A preliminary amendment. 14. <input checked="" type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power of attorney and/or change of address letter. 17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. <input checked="" type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: Express Mail Certificate; Copy of International Preliminary Examination Report; Statement Regarding Sequence Listing | | |

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|--------------|---|------------|--|------------|
| U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <div style="font-size: 2em; font-weight: bold; margin-left: 50px;">10/535522</div> | | INTERNATIONAL APPLICATION NO. PCT/EP2003/012941 | | ATTORNEY'S DOCKET NUMBER 100725-48 (KGB) | |
| 21. The following fees are submitted: | | | | | |
| <input checked="" type="checkbox"/> a) Basic national fee..... \$300.00 <input checked="" type="checkbox"/> b) Examination fee..... \$200.00 <input checked="" type="checkbox"/> c) Search fee..... \$500.00 | | | | <div style="border: 1px solid black; padding: 2px;">\$ 300.00</div> <div style="border: 1px solid black; padding: 2px;">\$ 200.00</div> <div style="border: 1px solid black; padding: 2px;">\$ 500.00</div> <div style="border: 1px solid black; padding: 2px;">\$ 1000.00</div> | |
| TOTAL OF ABOVE CALCULATIONS = \$1000.00 | | | | | |
| <input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof. | | | | | |
| Total Sheets | Extra sheets | Number of each additional 50 or fraction thereof (round up to a whole number) | RATE | | |
| - 100 = | /50 = | | x \$250.00 | \$ | |
| Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)). | | | | \$ | |
| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE | \$ | |
| Total claims | 24 - 20 = 4 | | x \$50.00 | \$ 200.00 | |
| Independent claims | 1 - 3 = | | x \$200.00 | \$ | |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable) | | | + \$360.00 | \$ | |
| TOTAL OF ABOVE CALCULATIONS = | | | | \$ | |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. | | | | | |
| SUBTOTAL = | | | | \$ | |
| Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)). | | | | + | |
| TOTAL NATIONAL FEE = | | | | \$ 1200.00 | |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property | | | | + | |
| TOTAL FEES ENCLOSED = | | | | \$ | |
| | | | | Amount to be refunded: | \$ |
| | | | | Amount to be charged: | \$ 1200.00 |
| a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>141263</u> in the amount of \$ <u>1200.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>141263</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. | | | | | |
| NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status. | | | | | |
| SEND ALL CORRESPONDENCE TO: Kurt G. Briscoe Customer No. 27384 875 Third Avenue - 18th Floor New York, NY 10022 Tel.: (212) 808-0700 | | | | | |
| | | | | SIGNATURE KURT G. BRISCOE NAME 33,141 REGISTRATION NUMBER | |

Attorney Docket No. 100725-48 (KGB)

This is a Utility Patent Application

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Alexander STEINKASSERER et al
SERIAL NO. : To Be Assigned [This is a 371 of PCT/EP2003/012941]
CUSTOMER NO. : 27384
FILED : Herewith
FOR : USE OF SOLUBLE FORMS OF CD83 AND NUCLEIC ACIDS
ENCODING THEM FOR THE TREATMENT OR PREBENTION
OF DISEASES
EXAMINER : To Be Assigned

EXPRESS MAIL CERTIFICATE

"Express Mail" mailing label number EV 586234264 US
Date of Deposit May 18, 2005

I hereby certify that the following items:

1. Transmittal Letter to the United States Designated/Elected Office (DO/EO/US)
Concerning a Submission Under 35 U.S.C. 371 – **CHARGE DEPOSIT ACCOUNT**
2. Application Data Sheet
3. Specification consisting of description (pages 1-37); Examples (pages 37-49); 11
Claims (pages 50-51); Abstract (page 52); 20 Sheets of Drawings; Sequence Listing
(pages 1-9)
4. Preliminary Amendment
5. Statement Regarding Sequence Listing
6. Diskette Containing Sequence Listing
7. Information Disclosure Statement
8. Form PTO 1449
9. Copy of International Search Report
10. Copy of International Preliminary Examination Report including Amended Sheets 1-7
of application and Amended Claims (28 Claims – Pages 1-5)
11. Return Receipt Postcard

are being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the: Mail Stop PCT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

NORRIS, McLAUGHLIN & MARCUS, P.A.

By Jennifer Archer
Jennifer Archer

Please acknowledge receipt of the following documents by placing the
mailroom date stamp on this self addressed postcard

| | |
|---|--------------------------------|
| Mailing Date: May 18, 2005 | Application No: To Be Assigned |
| Docket No. 100725-48 | Express Mail Label # EV |
| Filing Date: Herewith | Atty/Sect.: KGB/JA |
| Applicant : Alexander STEINKASSERER et al | |

Title of the Invention: Use of soluble forms of CD83 and nucleic acids...

Enclosures: - CHARGE FEES TO DEPOSIT ACCOUNT

1. Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Submission Under 35 U.S.C. 371
2. Application Data Sheet
3. Specification consisting of description (pages 1-37); Examples (pages 37-49); 11 Claims (pages 50-51); Abstract (page 52); ^{19 sp} 26 Sheets of Drawings; Sequence Listing (pages 1-9)
4. Preliminary Amendment
5. Statement Re: Sequence Listing & Diskette Containing Sequence Listing
6. Information Disclosure Statement; Form PTO 1449 and Copy of ISR
7. Copy of IPER including Amended Sheets 1-7 of application and Amended Claims (28 Claims - Pages 1-5)
8. Express Mail Certificate
9. Return Receipt Postcard

JCO6 Rec'd PCT/PTO 18 MAY 2005

10/535522